Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0)’s founder and CEO has stepped down from his position to join as executive chairman.
On Tuesday, the psychedelics company announced the appointment of Matt Stang to the role of executive chairman as well as the appointment of its COO Kevin Nicholson as the new CEO and a member of the board of directors. Nicholson is also the CEO of Ketamine Wellness Centers (KWC).
Stang owned and operated the cannabis news publication High Times for 17 years prior to founding Delic. He led the company to more than US$1.5 million in revenue last year and increased net assets 500 per cent from US$2.1 million in 2020 to US$10 million in its full year of operation.
“As the conversation around psychedelics evolves and gains momentum, Delic will continue to remain at the forefront. It is a privilege to continue as the company’s Executive Chairman and to work closely with the prestigious Board of Directors under Kevin’s leadership,” said Stang.
“I am highly confident that together we will continue to guide the company in its next phase of growth and further modernize healthcare.”
Read more: Sisters in Psychedelics host inaugural summit in Vancouver this September
Read more: WITHIN ‘Ceremonial Psychedelic Treatment Center’ opens in Texas
Nicholson is leading KWC, which is the largest ketamine provider in the U.S. and with his guidance, the company has generated annual revenue of more than $4 million and given 100,000 treatments to patients.
“Matt has been a tremendous, highly effective leader since co-founding Delic and has grown this company into the success it is today. I am grateful for his leadership and humbled to continue as CEO during such a pivotal moment in our industry,” said Nicholson.
“We are leveraging and growing our umbrella of businesses, including the nation’s largest network of ketamine clinics, KWC, and look forward to expanding in 2022,” he added.
“Alongside Delic’s Board of Directors, I am committed to continuing Delic’s mission of providing effective, affordable treatment options to anyone who needs them and educating on the safety and long-term benefits of these new therapies.”
Delic has granted 4,600,000 stock options to certain officers, directors, employees, and consultants to purchase 4,600,000 subordinate voting shares according to the company’s share compensation plan.
natalia@mugglehead.com
